🔍

Transgene Biotek Ltd (526139)

📊 BSE: 526139 🏢 Healthcare Service Provider 📢 Latest filing: 10 Oct 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Transgene Biotek's revenue was ₹0.1 Cr (+20.0% year on year, +20.0% on the previous quarter), and net profit ₹-0.4 Cr (a smaller loss than a year earlier); the operating margin was -97.0%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹0.1	+20.0%	+20.0%
Operating profit	₹-0.1	loss narrowed	loss narrowed
Net profit	₹-0.4	loss narrowed	loss narrowed
EPS (₹)	-0.05	loss narrowed	loss narrowed
Operating margin	-97.0%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Transgene Biotek Appoints Eswara Rao & Co as Statutory Auditors Following Casual Vacancy

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 10 Oct 2026, 12:38 PM

Transgene Biotek's Board approved the appointment of M/s. Eswara Rao & Co., Chartered Accountants, as Statutory Auditors on October 10, 2026. This appointment fills a casual vacancy created by the resignation of M/s. Vasavi & Co., Chartered Accountants. The appointment remains subject to approval by shareholders at an upcoming general meeting. Transgene Biotek reported annual revenue of ₹0.20 crore and a net loss of ₹1.65 crore for FY26.

Appointment of M/s. Eswara Rao & Co. (FRN: 000816S) approved on October 10, 2026
Casual vacancy caused by the resignation of outgoing auditors M/s. Vasavi & Co.
Partner Karra Pranavi (Membership No. 232994) to represent the statutory audit firm
Board meeting commenced at 11:00 AM and concluded at 12:30 PM on October 10, 2026

💡 Track the upcoming general meeting notice and voting outcome for shareholder approval of the new statutory auditor.

Transgene Biotek Reports Non-Applicability of Reg 32(1) for Q2 FY27 (Ended 30-Sep-2026)

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 03 Oct 2026, 06:38 PM

Transgene Biotek Ltd has submitted an intimation confirming the non-applicability of Regulation 32(1) of SEBI Listing Regulations for the quarter ended September 30, 2026. The company stated that no public issue, rights issue, or preferential issue was conducted during the reporting quarter. Consequently, a Statement of Deviation or Variation is not required. The company noted that it filed via PDF as the XBRL mode does not permit NIL entries.

Regulation 32(1) Statement of Deviation or Variation is not applicable for the quarter ended September 30, 2026
No funds were raised via public issue, rights issue, or preferential issue during the quarter ended September 30, 2026
Company cited an inability to submit via XBRL mode because the system does not allow NIL entries
Intimation submitted to BSE on October 3, 2026

💡 Track the company's upcoming Q2 FY27 financial results and operational updates, as this filing is purely a routine compliance disclosure.

Transgene Biotek Submits Reg 57(5) Non-Applicability Report for Q2 FY27

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 03 Oct 2026, 06:35 PM

Transgene Biotek has submitted a regulatory intimation confirming the non-applicability of Regulation 57(5) of SEBI LODR for the quarter ended September 30, 2026. The company stated that it has no non-convertible securities issued, meaning there are no interest, dividend, or principal payment obligations due. Transgene Biotek remains a micro-cap entity (market cap ₹21 Cr) with negative net worth of ₹-9 Cr and negligible TTM revenue. This filing represents purely routine quarterly compliance.

Filing confirms Regulation 57(5) of SEBI LODR is not applicable for quarter ended September 30, 2026
Company has zero issued non-convertible securities
No interest, dividend, or principal repayment obligations due or unpaid during the period

💡 Track the upcoming Q2 FY27 financial results for operational updates, given the company's negative net worth and minimal revenue base.

Transgene Biotek Board to Meet on Oct 10 to Appoint Statutory Auditor Post Resignation

🔵 WATCH ⭐ 4/10

BOARD_MEETING 📅 02 Oct 2026, 06:57 PM

Transgene Biotek has scheduled a Board of Directors meeting on October 10, 2026, to consider appointing M/s. Eswara Rao & Co. as Statutory Auditors. The appointment fills a casual vacancy caused by the resignation of M/s. Vasavi & Co. The company is financially distressed, reporting negative net worth of ₹-9 Cr, debt of ₹17 Cr, and TTM revenue close to ₹0 Cr. The proposed appointment remains subject to Audit Committee recommendation and shareholder approval.

Board meeting scheduled for Saturday, October 10, 2026, at 11:00 A.M.
Proposal to appoint M/s. Eswara Rao & Co. (FRN: 000816S) to fill casual auditor vacancy
Casual vacancy caused by the resignation of former auditors M/s. Vasavi & Co.
Proposed audit partner confirmed as Ms. Karra Pranavi (Membership No. 232994)

💡 Track the outcome of the October 10 board meeting and examine any disclosure regarding the reasons behind previous auditor M/s. Vasavi & Co.'s resignation.

Transgene Biotek Statutory Auditor M/s Vasavi & Co. Resigns Citing Pre-occupation

🔴 NEGATIVE ⭐ 7/10

MANAGEMENT 📅 23 Sep 2026, 07:46 PM

Transgene Biotek announced that its Statutory Auditors, M/s Vasavi & Co., Chartered Accountants (FRN: 020965S), have resigned with immediate effect via letter dated September 22, 2026. The auditor cited pre-occupation with other assignments and inability to devote sufficient time as the sole reason for resignation. The micro-cap company, currently reporting negative net worth of ₹-9 crore and TTM losses of ₹-2 crore, stated it will initiate steps to appoint a successor under the Companies Act, 2013.

Statutory Auditor M/s Vasavi & Co. resigned with immediate effect via letter dated 22nd September, 2026
Firm Registration Number (FRN) stated as 020965S
Auditor stated reason as pre-occupation in other assignments with no other material reasons disclosed
Company reported negative net worth of ₹-9 Cr and debt of ₹17 Cr in context

💡 Track the appointment of the incoming statutory auditor and verify disclosures in the upcoming quarterly filings for any qualification or audit adjustments.

Transgene Biotek Q1 Net Loss at ₹38.9 Lakhs; Revenue Remains Minimal at ₹6 Lakhs

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 07 Aug 2026, 11:55 AM

Transgene Biotek reported a marginal revenue of ₹6.00 Lakhs for the quarter ended June 30, 2026, compared to ₹4.95 Lakhs in the year-ago period. The company continues to be loss-making, posting a net loss of ₹38.90 Lakhs, though slightly narrowed from ₹43.37 Lakhs YoY. Finance costs of ₹28.95 Lakhs remain the largest expense head, consuming nearly five times the quarterly revenue. The company is also managing multiple legal proceedings across NCLT, SAT, and the Enforcement Directorate.

Revenue from operations for Q1 FY27 stood at ₹6.00 Lakhs.
Net loss for the quarter was ₹38.90 Lakhs, compared to a loss of ₹43.37 Lakhs in Q1 FY26.
Finance costs of ₹28.95 Lakhs accounted for 64.5% of total quarterly expenses.
Legal order in the Nitin Didwania matter requires payment of ₹92.99 Lakhs plus 6% interest; company has filed an appeal.
NCLT hearing adjourned to September 23, 2026, and ED hearing to September 10, 2026.

💡 Investors should closely monitor the outcomes of the NCLT and ED hearings in September 2026, as any adverse rulings could significantly impact the company's fragile ₹8 Cr net worth.

Transgene Biotek Q1 Net Loss of ₹38.9 Lakhs; ₹92.99 Lakh Legal Liability Under Appeal

🔵 WATCH ⭐ 6/10

EARNINGS 📅 07 Aug 2026, 11:42 AM

Transgene Biotek reported a marginal revenue of ₹6.00 lakhs for Q1 FY27, compared to ₹4.95 lakhs in the same quarter last year. The company remains loss-making with a net loss of ₹38.90 lakhs, largely due to finance costs of ₹28.95 lakhs which consume nearly five times the quarterly revenue. Multiple legal proceedings involving the NCLT, SAT, and Enforcement Directorate have been adjourned to August and September 2026. Crucially, the company is appealing a court order to pay ₹92.99 lakhs plus 6% interest in a loan-related dispute, a significant amount relative to its ₹8 crore net worth.

Revenue from operations for Q1 FY27 stood at ₹6.00 lakhs.
Net loss for the quarter was ₹38.90 lakhs, compared to a loss of ₹43.37 lakhs YoY.
Finance costs of ₹28.95 lakhs represent approximately 64% of total quarterly expenses.
Ordered to pay ₹92.99 lakhs plus 6% interest in the Nitin Didwania case; currently under appeal at Bombay High Court.
NCLT hearing adjourned to September 23, 2026, and SAT hearing to August 17, 2026.

💡 Investors should closely monitor the SAT hearing on August 17 and the ED Appellate Tribunal on September 10. The company's extremely low revenue base and high debt-servicing requirements make legal liabilities a critical risk factor.

Transgene Biotek Board Meeting on Aug 07 to Approve Q1 Results and Seek AGM Extension

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 23 Jul 2026, 04:44 PM

Transgene Biotek has scheduled a board meeting for August 07, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. A key agenda item is the proposal to seek an extension for holding the Annual General Meeting (AGM) for FY 2025-26. The company is currently in a precarious financial position with a TTM revenue of nearly zero and a high Debt-to-Equity ratio of 2.05. Investors should note the appointment of a new internal auditor for FY 2026-27 as part of the meeting's agenda.

Board meeting scheduled for August 07, 2026, to approve Q1 FY27 results.
Company seeking an extension for the Annual General Meeting (AGM) for the financial year 2025-26.
Appointment of internal auditor for the financial year 2026-27 to be considered.
Trading window closed from July 01, 2026, until 48 hours after results are made public.
Company reported a net loss of Rs 0.46 Cr in the most recent quarter (March 2026).

💡 Monitor the Q1 results on August 07 for any signs of revenue generation and review the specific reasons provided for the AGM extension request.

Transgene Biotek reports non-applicability of SEBI Regulation 57(4) for June 2026 quarter

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 22 Jul 2026, 01:44 PM

Transgene Biotek has filed a compliance report stating that SEBI Regulation 57(4) is not applicable for the quarter ended June 30, 2026. The company confirmed it has no outstanding non-convertible securities for which interest, dividend, or principal payments were due during this period. This is a routine administrative filing for companies without listed debt instruments. Financially, the company remains in a stressed position with a TTM net loss of Rs 2 Cr and a high debt-to-equity ratio of 2.05.

Regulation 57(4) declared not applicable for the quarter ended 30.06.2026
Zero non-convertible securities currently require interest or principal payments
Company maintains a total debt of Rs 17 Cr against a net worth of Rs 8 Cr
TTM revenue remains negligible at approximately Rs 0.26 Cr for FY25

💡 Focus on operational recovery and revenue generation in upcoming quarterly results rather than routine compliance filings, given the company's current TTM revenue of Rs 0 Cr.

Transgene Biotek reports Nil deviation in fund utilization for quarter ended June 30, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 22 Jul 2026, 01:40 PM

Transgene Biotek Ltd has submitted a NIL statement of deviation or variation for the quarter ended June 30, 2026. The company confirmed that no funds were raised through public issues, rights issues, or preferential issues during this period. Consequently, Regulation 32(1) of SEBI LODR is not applicable. The filing is a standard regulatory requirement to ensure transparency in the utilization of proceeds from capital raises.

Reporting period concluded on 30th June 2026
Zero funds raised via public, rights, or preferential issues during the quarter
Compliance filing under Regulation 32(1) of SEBI LODR Regulations, 2015
Company noted technical inability to file via XBRL due to NIL entry restrictions

💡 This is a routine administrative filing. Investors should focus on the upcoming quarterly financial results to assess operational performance since no new capital was infused.

Transgene Biotek Reports Non-Applicability of SEBI Reg 57(5) for June 2026 Quarter

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 22 Jul 2026, 01:37 PM

Transgene Biotek has filed a compliance report stating that Regulation 57(5) of SEBI (LODR) is not applicable for the quarter ended June 30, 2026. This regulation requires companies to certify the payment of interest, dividend, or principal for non-convertible securities. The company confirmed it has no such securities issued and therefore no outstanding payment obligations for the period. This is a standard administrative filing for companies without listed debt instruments.

Regulation 57(5) declared not applicable for the quarter ended June 30, 2026
Company confirmed it has not issued any Non-Convertible Securities
Zero unpaid interest, dividend, or principal obligations reported at quarter-end
Total debt remains at Rs 17 Cr as per latest financial context

💡 Investors should focus on the company's upcoming quarterly financial results to monitor revenue generation, as TTM revenue currently stands at Rs 0 Cr.

View All 526139 Announcements on Live Market Tracking →